Physician profile
Amanda Rosen
NPI 1508535337
$1,353.98
in general payments reported to CMS, 2019-2025
16 companies · $530 in 2025
The $530 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $64.78 · 2023: $254 · 2024: $505 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $368.11 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $186.66 | 2023-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $162.77 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $108.49 | 2024-2025 | |
| Madrigal Pharmaceuticals | $108.19 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $99.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $65.88 | 2024-2025 | Airsupra, Breztri |
| Biotronik Nro, INC. | $46.01 | 2024 | Prospera |
| Phathom Pharmaceuticals, INC. | $42.64 | 2025 | Voquezna |
| Astellas Pharma US INC | $42.55 | 2024 | Veozah |
| Ferring Pharmaceuticals INC. | $26.03 | 2023 | Rebyota |
| Shield Therapeutics INC | $23.12 | 2023 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.68 | 2025 | Xifaxan |
| Amgen INC. | $19.33 | 2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.86 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15.91 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.